|Bid||3.7500 x 1800|
|Ask||4.7300 x 800|
|Day's Range||4.2600 - 4.4700|
|52 Week Range||3.5000 - 10.4500|
|Beta (3Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.48|
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P.
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.-- -- Auryxia ® Revenue Increases to $29.1 Million for Q2’FY19, Up 21% from Q2’FY18 and Up 26% from Q1’FY19; ANDA Settlement Reinforces Strength of Auryxia IP; and, Vadadustat Achieves Key Regulatory Milestone with JNDA Submission Akebia Therapeutics , Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, ...
Akebia Therapeutics, Inc. (AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion & BF Biotech, Inc., have entered into a Settlement and License Agreement (Agreement) with Par Pharmaceutical, Inc., an Endo International company (Par). This settlement resolves patent litigation brought by Keryx and Panion in response to Par’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Auryxia (ferric citrate) tablets prior to the expiration of the applicable patents.
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 120,350 shares of Akebia’s common stock on July 31, 2019, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $4.19 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The big shareholder groups in Akebia Therapeutics, Inc. (NASDAQ:AKBA) have power over the company. Institutions often...
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2019, on Thursday, August 8, 2019 before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, August 8th to discuss its second quarter financial results and recent business updates. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 7274126.
Akebia Therapeutics, Inc. (AKBA), today announced that Mitsubishi Tanabe Pharma Corporation (MTPC), its development and commercialization collaboration partner in Japan for vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labor and Welfare in Japan for manufacturing and marketing approval of vadadustat as a treatment for anemia due to chronic kidney disease (CKD). The JNDA is the first regulatory submission for marketing approval of vadadustat and, if approved, is expected to lead to the first launch of vadadustat worldwide. This submission is supported by positive top-line data from MTPC’s two Phase 3, active-controlled, pivotal studies evaluating the efficacy and safety of vadadustat in Japanese subjects with anemia due to CKD and two additional Phase 3 single-arm studies in peritoneal and hemodialysis subjects, which were announced by Akebia and MTPC in March 2019.
Akebia Therapeutics, Inc. (AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, has been elected Chair of Kidney Care Partners (KCP), the nation’s largest kidney care coalition comprised of patient advocates, dialysis professionals, care providers, researchers and manufacturers. Mr. Butler will succeed current Chair, Dr. Allen R. Nissenson, Chief Medical Officer of DaVita Kidney Care, on January 1, 2020 for a two-year term.
Akebia Therapeutics, Inc. (AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line results from a pivotal Phase 3 comparative study evaluating Riona® Tablets 250mg (generic name in Japan: ferric citrate hydrate) for the treatment of iron deficiency anemia (IDA) in adult patients in Japan. JT and Torii hold the exclusive rights to develop and commercialize Riona in Japan.
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]
The Cambridge, Massachusetts-based company said it had a loss of 62 cents per share. Losses, adjusted for one-time gains and costs, were 44 cents per share. The results fell short of Wall Street expectations. ...
CAMBRIDGE, Mass.-- -- Net Product Revenue for Auryxia Increases to $23.1 Million for Q1’FY19, Up 12.1% from Q1’FY18; Full Enrollment of Phase 3 INNO 2 VATE Studies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations. Akebia Therapeutics , Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney ...
Akebia Therapeutics (AKBA) was a top stock pick by Seth Klarman (Trades, Portfolio) last quarter. Warning! GuruFocus has detected 4 Warning Signs with AKBA. Last June, Akebia agreed to combine with Keryx Biopharmaceuticals (KERX), of which Klarman was a major shareholder, controlling more than 20% of the fully diluted stock.